Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Article 2018 en
Authors
MS
Melody Smith
EG
Elena García-Martínez
MP
Michael Pitter
Abstract
1 min read
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Catherine Sautès‐Fridman, Isabelle Cremer, Jan H. ter Meulen, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi
Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Laurence Zitvogel, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.